Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Buys 10,000 Shares of Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the transaction, the director now directly owns 77,267 shares of the company’s stock, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Rezolute Trading Up 1.8 %

NASDAQ RZLT opened at $4.63 on Friday. Rezolute, Inc. has a 12 month low of $1.45 and a 12 month high of $6.19. The stock’s fifty day moving average price is $4.84 and its 200-day moving average price is $4.90. The stock has a market cap of $280.28 million, a P/E ratio of -3.80 and a beta of 1.10.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. As a group, analysts forecast that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

Several institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. boosted its position in shares of Rezolute by 699.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company’s stock valued at $12,377,000 after buying an additional 2,210,038 shares during the last quarter. Woodline Partners LP lifted its holdings in Rezolute by 2,817.1% in the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock valued at $5,338,000 after acquiring an additional 1,052,002 shares during the period. Susquehanna International Group LLP boosted its position in Rezolute by 749.0% in the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company’s stock worth $4,379,000 after purchasing an additional 788,349 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Rezolute during the 4th quarter valued at about $2,408,000. Finally, Nantahala Capital Management LLC increased its position in shares of Rezolute by 10.9% during the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company’s stock valued at $14,004,000 after purchasing an additional 280,861 shares during the last quarter. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Craig Hallum raised Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Wedbush reissued an “outperform” rating and set a $112.00 target price on shares of Rezolute in a research note on Monday, November 4th. JMP Securities lifted their price target on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research note on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $24.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.